
Leading the charge in cancer care
DDW Editor Reece Armstrong speaks to Michael Metzger, CEO of Syndax, about its work on developing therapeutics for challenging cancer targets. RA: What are the unmet needs in relapsed or refractory acute leukaemia. How great is this unmet need in paediatric patients? MM: Syndax is initially focused on two… Read More

